Bristol Myers Squibb to buy biopharmaceutical firm MyoKardia for $13.1bn

This article was originally published here

MyoKardia is engaged in the discovery and development of targeted therapies to treat serious cardiovascular diseases. As per terms of the merger deal, BMS subsidiary will begin a

The post Bristol Myers Squibb to buy biopharmaceutical firm MyoKardia for $13.1bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply